

# Anti-CD94 Antibodies for Enhanced Immune Response to Cancer Cells

Tech ID: 33619 / UC Case 2020-221-0

## TECHNOLOGY DESCRIPTION

Current cancer therapies often have limitations such as off-target effects, development of resistance, and limited efficacy against certain cancer types. There is a pressing need for therapies that can specifically target cancer cells and enhance the body's natural immune response against these malignant cells. The inventors have developed a novel therapeutic approach that uses anti-CD94 antibodies to deplete NK cells in a cancer patient.

## APPLICATION

This method enhances the targeting and killing of cancer cells by activated T cells, such as CD8+ effector T cells. The anti-CD94 antibodies can be administered in conjunction with other therapies like checkpoint inhibitors and antigen administration for cancer antigens. The antibodies can also be used to reduce an NK cell-mediated immune response to non-self cells or tissues transplanted in an individual, thereby enhancing the effectiveness of therapies such as CAR T-cell therapy.

## DATA AVAILABILITY

The inventors have shown specific binding regions and potential for high affinity binding to CD94.

## PATENT STATUS

Patent Pending

## CONTACT

Gemma E. Rooney  
[Gemma.Rooney@ucsf.edu](mailto:Gemma.Rooney@ucsf.edu)  
 tel: 415-625-9093.



## OTHER INFORMATION

### KEYWORDS

CD94, Antibody, Antibodies,  
 NK Cells, CD8+ T cells,  
 CAR-T cell therapy

### CATEGORIZED AS

- ▶ **Medical**
- ▶ Disease: Cancer
- ▶ Therapeutics

### RELATED CASES

2020-221-0

## ADDRESS

**UCSF**

**Innovation Ventures**

600 16th St, Genentech Hall, S-272,  
 San Francisco, CA 94158

## CONTACT

Tel:

[innovation@ucsf.edu](mailto:innovation@ucsf.edu)

<https://innovation.ucsf.edu>

Fax:

## CONNECT

 Follow  Connect

© 2024, The Regents of the University of  
 California

